Target family: Calcitonin receptors (type: gpcr)
Target: AMY<sub>3</sub> receptor

Ligand: AC187 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.679999828338623 pKB
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins.
Published in: Biochem Biophys Res Commun

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: adrenomedullin 2/intermedin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7 pEC50
Reference (Journal): The pharmacology of adrenomedullin 2/intermedin.
Published in: Br J Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
Published in: Mol Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins.
Published in: Biochem Biophys Res Commun

Ligand: α-CGRP-(8-37) (human) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.17 pKB
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor.
Published in: J Pharmacol Toxicol Methods

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: β-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor.
Published in: J Pharmacol Toxicol Methods

Ligand: calcitonin (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: no
Median affinity: 8.199999809265137 pKi
Reference (Journal): Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.
Published in: Mol Pharmacol

Ligand: CT-(8-32) (salmon) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pKB
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: davalintide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.890000343322754 pEC50
Reference (Journal): KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.
Published in: Am J Physiol Endocrinol Metab

Ligand: KBP-066 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action.
Published in: J Pharmacol Exp Ther

Ligand: KBP-088 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pEC50
Reference (Journal): KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.
Published in: Am J Physiol Endocrinol Metab

Ligand: pramlintide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2005)
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: [125I]BH-AMY (rat, mouse) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd